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Possible association between the C282Y and H63D mutations in the HFE gene and estrogen-dependent cancer risk was assessed. Genotyping
was performed using PCR amplification followed by digestion of products with specific restrictases. In a population of 260 healthy women
(permanent residents of the southwest European Russia), mutant allele frequencies at the C282Yand H63D sites were evaluated as 3.3 and 16.3%,
respectively. In patients with breast, ovarian, and endometrial cancer, C282Y frequencies were also low (1.0, 1.3, and 3.8%, respectively), and no
cancer risk associated with the C282Y mutation was found. Odds ratios for breast cancer risk associated with the H63D mutation increased
significantly with age: 0.5 in women below 48 years old, 1.0 in a range of 48–57 years, and 4.4 in older women (Ptrend=0.002). The latter value
was statistically significant (95% CI, 1.4–14.1), indicating that women bearing the H63D mutation may be at an increased breast cancer risk at an
age above 57 years. Preliminary results obtained in patients with two other estrogen-dependent malignancies revealed the same tendency to OR
increase with age in ovarian cancer patients (Ptrend=0.008), but no age-related OR differences in endometrial cancer patients.
D 2005 Elsevier B.V. All rights reserved.Keywords: HFE mutation; Iron metabolism; Oxidative stress; Cancer risk; Age1. Introduction
Development of hemochromatosis, a multi-organ disease
induced by a hereditary disorder of iron metabolism, is
associated with two missense alterations in the HFE gene: a
G to A transition at position 845 in exon 4, which results in a
cysteine to tyrosine substitution at amino acid 282 (the G845A,
or C282Y mutation), and a C to G change at position 187 in
exon 2, resulting in a histidine to aspartic acid substitution at
codon 63 (the C187G, or H63D mutation) [1]. It has been
suggested that chronic iron overload, in addition to long-known
hemochromatosis clinical manifestations (hepatic cirrhosis,
cardiomyopathy, diabetes mellitus, and others), may predispose
to cancer development—mainly due to oxidative stress created0925-4439/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2005.09.003
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E-mail address: kondrashova@mrrc.obninsk.ru (T.V. Kondrashova).in cells and tissues by extra iron stores, and also because iron
may be a nutritional requirement for cancer cells [2]. Studies on
correlation between the HFE mutations and cancer risk gave
contradictory results, some reporting a positive association [3–
5], and others showing no association [6–8].
This correlation may be particularly pronounced in estro-
gen-dependent cancers, since these malignancies are associated
with endogenous oxidative stress produced in target tissues by
estrogen metabolites, and HFE-related iron overload may
aggravate this stress [9]. To investigate this possibility, we
determined HFE C282Y and H63D genotypes in patients with
breast cancer (which is characterized by strong estrogen
dependence [10]), and compared results with the HFE
genotype distribution evaluated in healthy women. Also, we
report preliminary evaluations of the HFE mutation frequen-
cies in patients with two other estrogen-dependent cancers
(ovarian and endometrial).ta 1762 (2006) 59 – 65
http://www
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geographical variations [11], and we believe that this study
supplements published data (currently not abundant) on the
HFE mutation frequency in Russians.
2. Materials and methods
2.1. Subjects
Patient groups were composed of women admitted to the Medical
Radiological Research Center (MRRC) hospital between September 2001
and December 2004 with newly diagnosed breast, ovarian, or endometrial
cancer (100, 40, and 53 cases, respectively). Patients with history of any other
cancer were not included into the study. Blood samples from control subjects
were collected in the same period. The control group included 260 women who
had no any cancer or cancer history. Predominantly, they were volunteers
recruited among employees of the MRRC and other organizations where
authors’ acquaintances worked (158 subjects). In addition, the control group
included 83 women examined in the course of routine medical examinations
performed by MRRC physicians, and 19 women who presented to the MRRC
outpatient clinics with breast or gynecological disorders. Both cases and
controls, with rare exceptions, were residents of small towns (with 30–100
thousand inhabitants) in central European Russia to the southwest from
Moscow (mainly, Kaluga Region).
Simultaneously with blood donation, each participant completed a
questionnaire (under physician’s guidance), and provided her informed consent
for DNA analyses. The questionnaire included self-reported data on age, height,
weight, ethnicity, education, smoking habits, menstrual function, reproductive
history, breast and gynecological disorders, chronic diseases, use of hormone
preparations, and family history of cancer. However, in the course of
interviewing, it became clear that cancer patients were much better informed
on their health state than cancer-free women were. To avoid possible bias
resulting from dealing with non-comparable between cases and controls data,
the four latter characteristics were not included into analysis at this stage of the
study.
The study was approved by the Medical Radiological Research Center
Review Board.
2.2. Detection of HFE mutations
Blood samples were collected into EDTA-containing tubes and stored at
80 -C until DNA isolation. Isolated DNA was stored at 20 -C until
analysis. Genotypes at the G845A (C282Y) and C187G (H63D) sites were
determined by a PCR-based RFLP (restriction fragment length polymor-
phism) technique (generally, as described in [12]). Primers used to amplify a
389-bp fragment containing the G to A transition at position 845 in exon 4 of
the HFE gene (the C282Y mutation) were 5V-TGGCAAGGGTAAACA-
GATCC (forward) and 5V-CTCAGGCACTCCTCTCAACC (reverse). A
primer pair for amplification of a 208-bp fragment encompassing the C to
G transversion at nucleotide 187 (the H63D mutation) was 5V-ACATGGT-
TAAGGCCTGTTGC and 5V-GCCACATCTGGCTTGAAATT. The fragments
were amplified in 25-AL reactions containing 0.625 U of HotStarTaq
polymerase (Quiagen, Valencia, USA), 0.15 mM dNTPs, 0.2 AM primers,
and 50 ng of genomic DNA. Thermal cycling was carried out as follows: 15-
min denaturing at 95 -C, 30 amplification cycles (30 s at 94 -C, 1 min at 60
-C, and 30 s at 72 -C), and 10-min extension at 72 -C. At the first stages of
the study, C282Y and H63D amplifications were performed separately; later,
we combined both reactions in one tube, since conditions for both fragments
were similar and the difference in fragment length was enough to distinguish
between them clearly. Amplified fragments were digested for 4 h at 37 -C
with either RsaI or BclI for detection of the C282Y or H63D mutations,
respectively (both enzymes were purchased from Takara Biomedicals, Shiga,
Japan), in 10-AL reaction mixtures containing 4 AL of PCR products and 0.5
U of the respective enzyme. After RsaI digestion, a sequence containing G at
the G845A site was cut into fragments of 249 and 140 bp, whereas an A-
containing sequence resulted in 249- and 111-bp fragments. BclI digestionproduced 138- and 70-bp fragments in a sequence containing C at the C187G
site, whereas a G-containing product, which did not carry restriction sites for
this enzyme, remained intact at 208 bp in length. PCR products and digested
fragments were run on 8% polyacrylamide gels, stained with ethidium
bromide, and visualized by UV. Genotyping was performed blindly relative to
the case or control status of the blood sample donor.
2.3. Statistical analysis
Numerical variables were compared between study groups using the two-
sided t-test. The two-sided exact Fisher’s test was used for comparing
proportions. The Hardy–Weinberg equilibrium was assessed by the v2
goodness-of-fit test. The v2 criterion was also used in heterogeneity tests in
2K contingency tables. In comparisons of genotype proportions, contingency
tables were generated for the C282Y and H63D mutations separately. Since
homozygous HFE mutations (both at the C282Y and H63D sites) were rare,
they were combined with heterozygotes. Significance of a trend in proportions
was evaluated by the v2 test for trend. Evaluations of cancer risk associated
with the HFE mutations were based on odds ratios (OR) derived from 22
tables (wild type/wild type genotypes were regarded as a low-risk category).
Logit limits were used to evaluate 95% confidence intervals (CI). A group-
matching approach was applied for control of confounding: the study
population was stratified into subgroups, within which cases and controls
were balanced against putative confounding variables. To analyze OR estimates
in a series of resulting 22 tables, the expected number of cases carrying a
high-risk genotype was calculated for each table, based on the Mantel–
Haenszel common OR. Then, a variant of the v2 goodness-of-fit statistic for
logistic models was computed to assess homogeneity of ORs in the series. To
test for a trend in ORs, the single degree of freedom v2 for trend was used. In
the choice of statistical approaches, we followed recommendations given in
[13].
3. Results
The primary attention in this study was focused on breast
cancer, and the main analysis refers to the breast cancer group.
Also, we show data obtained in ovarian and endometrial cancer
patients. These data are preliminary, because of the insufficient
group sizes; yet, they may be of interest for comparing
genotyping results between various types of estrogen-depen-
dent malignancies.
Characteristics of the study groups, including selected
cancer risk factors and demographic features, are shown in
Table 1.
The mean variables that were significantly different
between controls and breast cancer cases included age (and,
consequently, the proportion of postmenopausal women), age
at menopause, and BMI. All these indices were higher in
patients than in controls. Demographic characteristics (eth-
nicity, education level, smoking habits, and parity) were
similar in the study groups, indicating that even if any bias
associated with selection of the control group (the ‘‘healthy
volunteer effect’’) was introduced into the study, it was not
essential.
Table 2 presents genotype distributions at the HFE C282Y
and H63D loci, as well as C282Y and H63D allele fre-
quencies, in healthy women and cancer patients. The
genotypes were in the Hardy–Weinberg equilibrium in each
group (all P values exceeded 0.6). The only C282Y
homozygote for all 453 women genotyped for this mutation
was found in a 61-year old endometrial cancer patient with
the wild-type H63D genotype. Compound C282Y/H63D
Table 1
Characteristics of study subjects (controls, healthy women; BC, OC, and EC patients, women with breast, ovarian, and endometrial cancer, respectively)
Controls (n =260) BC patients (n =100) P value OC patients (n =40) EC patients (n =53)
Agea, years 44.9T10.3 (25–75) 53.2T11.6 (27–75) 109 49.6T16.1 (16–74) 56.4T10.5 (27–78)
Age at menarchea,b, years 13.8T1.4 (10–18) 13.9T1.7 (11–19) >0.10 13.7T1.4 (12–18) 13.6T1.5 (10–17)
Postmenopausalc, n (%) 68 (26.2) 62 (62.0) 1011 25 (62.5) 36 (67.9)
Age at menopausea,d, years 48.2T4.2 (32–56) 49.5T3.8 (41–58) 0.01 49.8T3.2 (43–55) 50.4T3.9 (42–59)
Nulliparouse, n (%) 16 (6.2) 2 (2.0) >0.10 7 (17.5) 9 (17.0)
BMIa, kg/m2 27.2T5.3 (16.9–46.6) 28.8T5.5 (19.1–47.7) 0.01 27.2T6.3 (18.8–47.0) 32.2T6.7 (20.3–52.3)
Smokers, n (%) 28 (10.8) 11 (11.0) >0.10 3 (7.5) 3 (5.7)
East Slavicsf, n (%) 250 (96.2) 96 (96.0) >0.10 36 (90.0) 51 (96.2)
Higher school graduatesg, n (%) 99 (38.1) 35 (35.0) >0.10 10 (25.0) 18 (34.0)
P values are given for comparisons between BC patients and controls.
a MeanTSD (range).
b Data were missing for 28 control subjects, 3 BC patients, 1 OC patient, and 1 EC patient.
c Including women with amenorrhea period up to 6 months.
d Data were missing for 2 control subjects, and 1 OC patient.
e Data were missing for 2 control subjects, and 1 BC patient.
f East Slavics were predominantly Russians (over 90% in each group), Ukrainians, and Belarusians.
g As opposed to subjects with secondary and elementary education (these two categories were combined, since in total there were only 8 subjects with elementary
education); data were missing for 20 control subjects, and 1 OC patient.
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each of the breast and endometrial cancer groups, and none in
the ovarian cancer group. Differences from the control values
in the genotype distributions, as well as in the mutant allele
frequencies, were statistically insignificant in each patient
group.
Age, BMI, age at menarche, and age at menopause are
known to influence breast cancer risk [10], and, presumably,
distribution of each of these variables in a population may be
associated with the HFE genotype; thus, these characteristics
may represent classic confounding factors. The case and
control samples were not balanced in respect of most of
these factors. Since obesity is more frequent in older persons,Table 2
HFE genotype distribution in healthy women (controls) and patients with









C282Y genotypes, n (%)
Wild/wild 243 (93.5) 98 (98.0) 39 (97.5) 50 (94.3)
Wild/C282Y 17 (6.5) 2 (2.0) 1 (2.5) 2 (3.8)
C282Y/C282Y 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.9)
Pb 0.11 0.48 0.99
C282Y allele, % 3.3T0.8 1.0T0.7 1.3T1.2 3.8T1.9
Pc 0.09 0.32 0.79
H63D genotypes, n (%)
Wild/wild 180 (69.2) 67 (67.7) 30 (75.0) 41 (77.4)
Wild/H63D 75 (28.8) 30 (30.3) 9 (22.5) 10 (18.9)
H63D/H63D 5 (1.9) 2 (2.0) 1 (2.5) 2 (3.8)
Pb 0.78 0.58 0.32
H63D allele, % 16.3T1.6 17.2T2.7 13.8T3.9 13.2T3.3
Pc 0.79 0.56 0.42
a For one patient, H63D genotyping was not successful.
b Exact Fisher’s test for the proportions of subjects bearing at least one
mutant allele (orthogonal comparisons with controls).
c Exact Fisher’s test for the mutant allele proportions (orthogonal compar-
isons with controls).and since the mean ages at menarche and at menopause are,
in general, dependent on the calendar date of birth, the
differences in these factors could ensue, at least partly, from
the difference in age distributions. Thus, we had to deal with
correlated confounding factors. To control for them, we
chose a ‘‘group-matching’’ approach (or stratified analysis),
because logistic regression, though a more powerful statisti-
cal tool, may be error-prone in cases of correlated regression
variables (see pp. 233–236 in [13]). However, stratified
analysis was only applied to H63D data, as the low
population frequency of the C282Y mutation did not allow
reasonable stratification.
To take an initial look at possible association of the above-
mentioned factors with the H63D genotype, we dichotomized
the control group into carriers of a H63D mutation (homo-
and heterozygotes combined) and wild-type homozygotes
(Table 3). Of all the putative confounders compared between
the resulting subgroups, only the age differences were
statistically significant, indicating that age was the most
potent confounder. This impression was further indirectly
supported by results of tests for heterogeneity in proportions
of the mutant genotypes in breast cancer patients and healthy
controls stratified in various ways: by menopausal status, age,
BMI, or other factors (v2 tests in 24 tables). All these tests
gave negative results (data not shown), with the exception of
age stratification: percentages of the mutant genotypes in
cases and controls older and younger than 54 years (the
median age in the breast cancer group) appeared heteroge-
neous (P=0.02).
These data suggested that the difference in age distributions
between breast cancer patients and healthy controls should be
the factor of major concern to further analysis. Since there were
many more controls than cases, we stratified both groups by the
age tertiles in breast cancer patients. Table 4 shows that this
stratification yielded acceptable matching of cases and controls
within each of the three age strata for each of the putative
confounders.
Table 3
Selected characteristics of the control group by H63D genotype (Wild, wild-
type homozygotes; Mutant, carriers of at least one H63D allele)
Wild (n =180) Mutant (n =80) P
Agea, years 45.7T10.7 43.0T9.3 0.04
Age at menarchea 13.8T1.4 13.8T1.3 >0.10
Postmenopausal, N (%) 50 (27.8) 18 (22.5) >0.10
Age at menopausea 48.3T4.7 47.8T2.6 >0.10
BMI1, kg/m2 27.3T5.4 26.9T5.2 >0.10
a MeanTS.D.
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between controls and breast cancer cases within each of the
matched age groups is presented in Table 5. In healthy women,
the mutant frequency tended to decrease with age; however,
neither the differences between the age groups (homogeneity
test in a 23 contingency table) nor the trend of the decrease
were statistically significant. Data in the three age groups of
breast cancer patients were inhomogeneous at a borderline
significance; moreover, the trend of an age-related increase in
the mutant frequency (that is, an opposite tendency, as
compared with controls) was significant at P=0.018. Odds
ratios shown in Table 5 were calculated in each age stratum
separately (e.g., cases aged 25–47 years were compared with
controls aged 25–47 years, and so on). The stratum-specific
OR values were significantly heterogeneous, indicating that a
summary measure of relative risk would be misleading. The
trend to OR increase with age was also significant. In the two
first age strata, the ORs did not differ from 1, within their
respective confidence intervals; however, an estimate in the
oldest age group (OR=4.4) appeared statistically significant.
For comparison, Table 5 shows similar data for ovarian and
endometrial cancer patients. As noted above, the numbers of
patients with these malignancies were insufficient for reliable
OR evaluations (currently, we continue collecting DNA
samples for the analysis). In ovarian cancer patients, these
preliminary results indicated the same tendency as was found
in the breast cancer group: cancer risk in H63D carriers
increased with age. No such tendency was visible in
endometrial cancer patients.Table 4
Stratification of the control (Co) and breast cancer (BC) groups by age (values clo
Aged 25–47 years Aged 48–5
Co (n =167) BC (n =32) P Co (n =62)
Agea, years 38.8T6.1 39.7T5.7 >0.10 51.6T2.8
Age at menarchea 13.9T1.4 13.4T1.2 0.07 13.5T1.2
Postmenopausalc 6 (3.6) 4 (12.5) 0.06 31 (50.0)
Age at
menopausea
42.8T5.5 43.8T2.1 >0.10 49.2T3.1
Nulliparousc 13 (7.8) 1 (3.1) >0.10 2 (3.2)
BMIa, kg/m2 26.0T5.1 26.2T5.1 >0.10 30.0T5.4
Slavicsc 160 (95.8) 32 (100.0) >0.10 60 (96.8)
Smokersc 24 (14.4) 8 (25.0) >0.10 3 (4.8)
Higher school
graduatesc
63 (42.0) 12 (37.5) >0.10 21 (35.6)
a MeanTS.D.
b 0.05<P <0.06.
c n (%).4. Discussion
Prevalence of the C282Y mutation in various ethnic
populations has been reported in numerous studies (reviewed,
for example, in [11]). Published data show an overall decrease
of the mutant frequency from northwest Europe both to the
south and east: from as high as 0.142 in Ireland [14] to zero in
northern Greece [15], and Japan [16]. As for Slavic popula-
tions, values reported for the C282Y allele frequency were
0.031 in a sample of 871 Poles [17] and 0.037 in a sample of
150 Russians residing in Siberia [18]. An estimate of 0.033
obtained in this study is virtually consistent with the cited
results.
Reported frequency of the mutant H63D allele also shows
pronounced ethnic dependence, but, compared with that of the
C282Y, the rate is relatively high in Europe (around 0.160 in
Spain [19] and northern Italy [20], 0.125 in Sicily [20], and
0.090 in Greece [15]), whereas in Asian populations the
mutation is rare (below 0.01 in Japan [16]). The estimations
reported for Polish and Russian populations are 0.162 and
0.133, respectively [17,18]. In frames of statistical errors, they
are quite similar to our estimate (0.163).
Evaluation of the population frequencies of the HFE
mutations made in this study was based on genotyping 260
women residing mostly in Kaluga Region and adjacent areas
in southwest European Russia. This sample was 96.2% East
Slavics (predominantly Russians, plus Ukrainians and
Belorussians). As compared with data reported by the Russian
Federal Service of State Statistics in 2002 [21], this percentage
coincided with 96.3% in Kaluga Region, and was fairly close to
93.8% in the Central Federal District. Since published data did
not show sex-related difference in the HFE genotype distribu-
tions [22,23], we believe that our sample was representative
enough to provide an evaluation of the C282Y and H63D
mutation frequencies in healthy population of central European
Russia.
Carriers of the mutant HFE alleles are prone to accumula-
ting extra iron in body tissues. The correlation between mutant
genotype and iron overload is more distinct for C282Y than forsest to the age tertiles in cases were used as cut-off points)
7 years Aged 58–75 years
BC (n =32) P Co (n =31) BC (n =35) P
52.8T2.8 0.05b 64.3T4.1 65.5T5.2 >0.10
13.7T1.5 >0.10 14.0T1.4 14.4T2.1 >0.10
22 (68.8) 0.08 31 (100.0) 35 (100.0) >0.10
49.1T3.5 >0.10 48.2T4.2 50.2T3.7 0.053
0 (0.0) >0.10 1 (3.3) 1 (2.9) >0.10
30.1T6.1 >0.10 27.9T4.4 29.7T4.2 >0.10
31 (96.9) >0.10 30 (96.8) 33 (94.3) >0.10
2 (6.3) >0.10 1 (3.2) 1 (2.9) >0.10
14 (45.2) >0.10 15 (48.4) 9 (25.7) 0.06
Table 5
Percentage of the mutant H63D genotypes (homo-plus heterozygotes) and cancer risk in three age strata




Controls 32.9 (55/112) 32.3 (20/42) 16.1 (5/26) 0.169 0.117
BC patients 18.8 (6/26) 31.3 (10/22) 45.7 (16/19) 0.061 0.018
ORBC (95% CI) 0.5 (0.2–1.2) 1.0 (0.4–2.4) 4.4 (1.4–14.1) 0.011 0.002
OC patients 12.5 (2/14) 22.2 (2/7) 40.0 (6/9) 0.205 0.078
OROC (95% CI) 0.3 (0.1–1.3) 0.6 (0.1–3.2) 3.5 (0.9–14.2) 0.040 0.008
EC patients 40.0 (4/6) 10.5 (2/17) 25.0 (6/18) 0.184 0.612
OREC (95% CI) 1.4 (0.4–5.0) 0.3 (0.1–1.2) 1.7 (0.5–6.6) 0.116 0.597
In brackets, ratios of the mutant (homo-plus heterozygote) to the wild-type/wild type genotypes. Controls, healthy women; BC, OC, and EC patients, women with
breast, ovarian, and endometrial cancer, respectively. In each age stratum, carriers of the wild-type/wild-type genotypes (within the stratum) were regarded as a
reference category (OR=1.0).
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H63D homo- and heterozygotes have also been published
[28,29]. Results of a large epidemiological study indicated
increased cancer risk in subjects with elevated body iron level
[2]. Stevens et al. [30] further hypothesized that the association
between the HFE mutations and cancer risk may be particu-
larly pronounced for breast cancer. The latter is known to be
related to free-radical-mediated damage produced in breast
tissue by estrogen metabolites [10], and this damage may be
aggravated by extra iron stores. In particular, it was shown that
redox cycling of estrogen metabolites released Fe2+ ions from
ferritin, which resulted in generating additional free radicals
[9]. Following the same arguments, an increased risk associa-
ted with the mutant HFE can be assumed for other oxidative
stress-related malignancies, in particular, ovarian and endome-
trial cancers, both of which are estrogen-dependent [31,32].
Results indicating a possible role of genes involved in
oxidative stress control in ovarian or endometrial cancer
development have been published [32,33].
We could not find either studies addressing ovarian and
endometrial cancers in relation to HFE mutations or reports on
H63D distribution in breast cancer patients. However, an
increased breast cancer risk associated with the mutant C282Y
allele has recently been reported [5]. In our study, no
significant differences in the C282Y frequencies were found
between breast cancer patients and healthy women (the mutant
frequency was even somewhat lower in cases than in controls;
Table 2). In effect, this is not contradictory to the cited report,
as statistical power of our study was obviously insufficient to
detect effects of the C282Y, a mutation characterized by a
relatively low population frequency. The mutant C282Y
frequencies preliminary evaluated in smaller groups of ovarian
and endometrial cancer patients also did not differ significantly
from the control value. It should be noted that all comparisons
related to the C282Y frequencies were made between the case
and control groups that were not matched for confounding
factors.
For the H63D mutation, due to its higher population
frequency, it was possible to apply stratified analysis and
perform more accurate comparisons between breast cancer
cases and controls. Stratification by age allowed obtaining
three strata such that, within each stratum, breast cancer cases,and controls were matched not only for age but also for other
putative confounders (Table 4). It appeared that ORs for breast
cancer were significantly inhomogeneous in the three strata:
they increased from 0.5 in women aged below 48 years through
1.0 in women aged 48 to 57 years to 4.4 in older women (Table
5). The latter value was statistically significant, indicating that
carriers of the H63D mutation aged above 57 years were at
increased risk of developing breast cancer. The smooth positive
trend in stratum-specific ORs (which is generally regarded as
an indication of causality of an association) gave additional
support to this conclusion.
These OR values are not adjusted for alcohol consumption
(unfortunately, a question on alcohol consumption was not
included into our questionnaire); however, this factor is not
likely to be a source of serious bias, since reported relative risk
for breast cancer in moderate drinkers vs. nondrinkers (1.41
[34]) is essentially lower than OR of 4.4 found in this study for
elderly carriers of the H63D allele.
A similar pattern of genotype distributions in the same age
strata was observed in ovarian cancer patients (the age-related
trend was also significant) but not in women with endometrial
cancer. It would be preliminary to discuss this difference
between breast and ovarian cancer, on the one hand, and
endometrial cancer, on the other; probably, it may be
attributable to an important dissimilarity of endometrium from
breast and ovarian tissue (periodical tissue loss during
menstruation).
It is not of surprise that H63D-associated breast cancer risk
was revealed only in elder women. Iron overload increases
with age, and its deleterious effects may become more apparent
in the elderly. In women, age-related changes in iron
accumulation may be even more pronounced because meno-
pause transition puts an end to significant iron loss that occurs
in women of reproductive age due to menstruation and
pregnancies.
We would like to add some conjectural comments on why
the H63D frequency in breast cancer patients increased with
age (with a significant trend), whereas in healthy controls the
pattern tended to be opposite (though neither the differences
between the age strata nor the trend were significant). Health
effects of HFE mutations are ambiguous. From the first
perspective, they predispose to diseases associated with iron
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protected against diseases connected with iron deficiency ([11],
and references herein). One might assume that, whereas the
former (adverse) effect of the mutant genotype is more
pronounced in older subjects, at younger age the latter
(favorable) health effect prevails, especially in women. An
OR value of 0.5 obtained in the youngest age strata (25–47
years) was not reliable statistically; yet, some health-protecting
role (not necessarily specific for breast cancer) of HFE
mutations at a young age seems plausible. Similar data were
reported for colon cancer risk in subjects bearing HFE
mutations: OR values in age ranges of <50, 50–69, and 70
years were 0.59, 1.29, and 1.90, respectively (only the latter
value was statistically significant) [4]. In published works, we
did not find straightforward data either confirming or contra-
dicting this assumption. Among indirectly relevant studies, we
found, on the one hand, data on a shortened life expectancy in
HFE heterozygotes [36]; on the other hand, data showing no
under-representation of HFE mutations in women aged 85
years and older [23], and a report on a trend for an increased
H63D frequency in centenarian women [37]. No significant
differences were found in prevalence of HFE mutations in a
large sample stratified by the age groups 12–19, 20–39, 40–
59, and 60 years [22]. Evidently, not only a much larger than
ours but a specially designed study is required to verify the
above assumption.
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